KURA
Kura Oncology, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +5.9% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | -1 | 303.62K | $3.00M | n/a | −1 |
| Q2 2026 | 85 | +3 | 46.85M | $513.57M | +7 | −4 |
| Q1 2026 | 85 | 0 | 43.54M | $354.05M | +5 | −5 |
| Q4 2025 | 85 | 0 | 47.00M | $488.20M | +1 | −1 |
| Q3 2025 | 15 | -1 | 31.70M | $280.57M | n/a | −1 |
| Q2 2025 | 13 | 0 | 25.43M | $146.75M | n/a | n/a |
| Q1 2025 | 10 | 0 | 9.58M | $63.25M | n/a | n/a |
| Q4 2024 | 10 | -1 | 11.52M | $100.37M | +1 | −2 |
| Q3 2024 | 10 | 0 | 4.92M | $96.24M | +1 | −1 |
| Q2 2024 | 10 | n/a | 4.04M | $83.12M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 9.52M | +0.5% | $84.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 5.47M | +2.2% | $48.40M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 3.34M | +10.1% | $29.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Goldman Sachs Group ✦ | 2.61M | n/a | $23.14M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | AQR Capital Management ✦ | 2.24M | +138.1% | $19.84M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 6 | Millennium Management ✦ | 2.09M | -20.1% | $18.53M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.05M | +1.7% | $18.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 1.81M | n/a | $16.05M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Renaissance Technologies ✦ | 865.31K | -18.1% | $7.66M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 808.82K | +122.1% | $7.16M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Marshall Wace ✦ | 488.75K | +1053.7% | $4.33M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 204.72K | -34.0% | $1.81M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 86.87K | +92.2% | $768,836 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | JPMorgan Chase ✦ | 68.07K | n/a | $602,438 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 15 | T. Rowe Price ✦ | 41.96K | +6.0% | $372,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| D. E. Shaw & Co. | $811,914 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 217 holders, 84.35M shares, $677.88M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Officer, Director · President and CEO · 100.00K sh @ 12.39 · $1.24M
Officer, Director · President and CEO · 100.00K sh @ 11.12 · $1.11M
Open-market sales (S)
Officer · 3.67K sh · $39,437
Officer · 28.80K sh · $309,567
Officer · 15.43K sh · $165,852
Officer · 4.61K sh · $48,361
Officer · 8.44K sh · $88,618
Officer · 6.91K sh · $72,494
Officer · 9.02K sh · $94,686
Officer · 8.00K sh · $84,498
Officer · 12.45K sh · $130,670
Officer · 20.73K sh · $224,514
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology